BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37189432)

  • 1. Screening and Identification of a Prognostic Model of Ovarian Cancer by Combination of Transcriptomic and Proteomic Data.
    Jiang J; Chen Z; Wang H; Wang Y; Zheng J; Guo Y; Jiang Y; Mo Z
    Biomolecules; 2023 Apr; 13(4):. PubMed ID: 37189432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a survival-related signature for sarcoma patients through integrated transcriptomic and proteomic profiling analyses.
    Zhang B; Yang L; Wang X; Fu D
    Gene; 2021 Jan; 764():145105. PubMed ID: 32882333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of an Immune-Related Prognostic Signature for Ovarian Cancer Based on Weighted Gene Coexpression Network Analysis.
    An Y; Yang Q
    Biomed Res Int; 2020; 2020():7594098. PubMed ID: 33381581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
    Peng Y; Wang H; Huang Q; Wu J; Zhang M
    J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
    Zhao Q; Fan C
    BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer.
    Jiao J; Jiang L; Luo Y
    Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
    Song Y; Qu H
    BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq.
    Zhang D; Lu W; Cui S; Mei H; Wu X; Zhuo Z
    J Ovarian Res; 2022 Nov; 15(1):123. PubMed ID: 36424614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Machine learning-assisted analysis of epithelial mesenchymal transition pathway for prognostic stratification and immune infiltration assessment in ovarian cancer.
    Li Q; Xiao X; Feng J; Yan R; Xi J
    Front Endocrinol (Lausanne); 2023; 14():1196094. PubMed ID: 37404304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Prognostic Biomarkers for Glioblastoma Based on Transcriptome and Proteome Association Analysis.
    Wang J; Yan S; Chen X; Wang A; Han Z; Liu B; Shen H
    Technol Cancer Res Treat; 2022; 21():15330338211035270. PubMed ID: 35538679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer.
    Shen S; Wang G; Zhang R; Zhao Y; Yu H; Wei Y; Chen F
    EBioMedicine; 2019 Feb; 40():318-326. PubMed ID: 30594555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel gene signatures for prognosis prediction in ovarian cancer.
    Bao M; Zhang L; Hu Y
    J Cell Mol Med; 2020 Sep; 24(17):9972-9984. PubMed ID: 32666642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a RNA-seq-based signature to improve prognostics for uterine sarcoma.
    Zhou JG; Zhao HT; Jin SH; Tian X; Ma H
    Gynecol Oncol; 2019 Dec; 155(3):499-507. PubMed ID: 31662204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of prognostic immune-related gene signature associated with tumor microenvironment of colorectal cancer.
    Wang Y; Li W; Jin X; Jiang X; Guo S; Xu F; Su X; Wang G; Zhao Z; Gu X
    BMC Cancer; 2021 Aug; 21(1):905. PubMed ID: 34364366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a multi-gene-based immune prognostic signature in ovarian Cancer.
    Cao T; Shen H
    J Ovarian Res; 2021 Jan; 14(1):20. PubMed ID: 33509250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two novel prognostic models for ovarian cancer respectively based on ferroptosis and necroptosis.
    Li Y; Gong X; Hu T; Chen Y
    BMC Cancer; 2022 Jan; 22(1):74. PubMed ID: 35039008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
    Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
    Front Immunol; 2022; 13():943389. PubMed ID: 36003381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
    Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
    Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.
    Zhang Y; Liu J; Raj-Kumar PK; Sturtz LA; Praveen-Kumar A; Yang HH; Lee MP; Fantacone-Campbell JL; Hooke JA; Kovatich AJ; Shriver CD; Hu H
    Breast Cancer Res Treat; 2020 Dec; 184(3):689-698. PubMed ID: 32880016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.